These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8630228)

  • 1. DNA methylation, molecular genetic, and linkage studies in prostate cancer.
    Jarrard DF; Bova GS; Isaacs WB
    Prostate Suppl; 1996; 6():36-44. PubMed ID: 8630228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetics of prostate cancer.
    Isaacs WB
    Cancer Surv; 1995; 25():357-79. PubMed ID: 8718527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biology of prostate cancer progression.
    Isaacs WB; Bova GS; Morton RA; Bussemakers MJ; Brooks JD; Ewing CM
    Cancer Surv; 1995; 23():19-32. PubMed ID: 7621457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of prostate cancer.
    Visakorpi T
    Ann Chir Gynaecol; 1999; 88(1):11-6. PubMed ID: 10230676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.
    Asatiani E; Huang WX; Wang A; Rodriguez Ortner E; Cavalli LR; Haddad BR; Gelmann EP
    Cancer Res; 2005 Feb; 65(4):1164-73. PubMed ID: 15734999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
    Li LC; Carroll PR; Dahiya R
    J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
    Cairns P; Okami K; Halachmi S; Halachmi N; Esteller M; Herman JG; Jen J; Isaacs WB; Bova GS; Sidransky D
    Cancer Res; 1997 Nov; 57(22):4997-5000. PubMed ID: 9371490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complex genetic epidemiology of prostate cancer.
    Schaid DJ
    Hum Mol Genet; 2004 Apr; 13 Spec No 1():R103-21. PubMed ID: 14749351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci.
    Witte JS; Suarez BK; Thiel B; Lin J; Yu A; Banerjee TK; Burmester JK; Casey G; Catalona WJ
    Prostate; 2003 Dec; 57(4):298-308. PubMed ID: 14601026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation differences associated with tumor tissues identified by genome scanning analysis.
    Liang G; Salem CE; Yu MC; Nguyen HD; Gonzales FA; Nguyen TT; Nichols PW; Jones PA
    Genomics; 1998 Nov; 53(3):260-8. PubMed ID: 9799591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer.
    Kuczyk MA; Serth J; Bokemeyer C; Schwede J; Herrmann R; Machtens S; Grünewald V; Höfner K; Jonas U
    Oncol Rep; 1998; 5(1):213-6. PubMed ID: 9458379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
    Singal R; Ferdinand L; Reis IM; Schlesselman JJ
    Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xq27-28 deletions in prostate carcinoma.
    Kibel AS; Faith DA; Bova GS; Isaacs WB
    Genes Chromosomes Cancer; 2003 Aug; 37(4):381-8. PubMed ID: 12800149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of proximal 6q deletions in prostate cancer.
    Cooney KA; Wetzel JC; Consolino CM; Wojno KJ
    Cancer Res; 1996 Sep; 56(18):4150-3. PubMed ID: 8797584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas.
    Chen C; Frierson HF; Haggerty PF; Theodorescu D; Gregory CW; Dong JT
    Genomics; 2001 Oct; 77(3):135-44. PubMed ID: 11597138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1.
    Dai Q; Deubler DA; Maxwell TM; Zhu XL; Cui J; Rohr LR; Stephenson RA; Brothman AR
    Genomics; 2001 Feb; 71(3):324-9. PubMed ID: 11170749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
    Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
    Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers.
    Zuhlke KA; Madeoy JJ; Beebe-Dimmer J; White KA; Griffin A; Lange EM; Gruber SB; Ostrander EA; Cooney KA
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5975-80. PubMed ID: 15447980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.